BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
about
Evolutionary dynamics of cancer in response to targeted combination therapyDistinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signallingTunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Genomic diversity of colorectal cancer: Changing landscape and emerging targetsNew therapeutic strategies for BRAF mutant colorectal cancersBRAF Mutation in Colorectal Cancer: An UpdateSimilar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistanceMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsToward a Molecular Classification of Colorectal Cancer: The Role of BRAFThe dynamic nature of the kinomeTargeted therapies in development for non-small cell lung cancerCIViC databaseComplexities of TGF-β targeted cancer therapy.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Novel small molecule Raf kinase inhibitors for targeted cancer therapeuticsExome sequencing identifies BRAF mutations in papillary craniopharyngiomasRegistered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersCombinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocksPDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.The stable traits of melanoma genetics: an alternate approach to target discoveryRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Acylglycerol kinase augments JAK2/STAT3 signaling in esophageal squamous cellsBRAFV600E negatively regulates the AKT pathway in melanoma cell lines.The MAPK pathway across different malignancies: a new perspective.Kras as a key oncogene and therapeutic target in pancreatic cancerNext generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistanceInsight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanomaTumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidenceEGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
P2860
Q21128788-81B3C68C-81BD-4727-8463-5123CEBE9E69Q24314807-571ABDD3-E4BD-465A-AFC0-C33659A6373BQ24315032-E45C3978-B53C-4DB2-B952-758C96BC6A8EQ26739052-649EFCE2-3FBB-425A-ABCC-597380786713Q26772277-1254DF2F-0770-422B-80B4-50129E2A709FQ26781926-A41F6F70-4190-445C-BEA7-0CA35495F10DQ26795609-FB2E3120-A672-4C71-BF4E-FFF5F5687812Q26795735-DC6F915D-44D5-4205-BA0B-F300D9936F00Q26827212-D6634D8D-79B0-4CF9-BA02-BB56E60914C8Q26852588-D1381957-793C-49A3-819C-B75B533E639EQ27022852-935CCB9A-8A0C-4163-B559-6312D42854F2Q27612411-B2A57C56-2E4F-4F7C-8E5A-9540D136668BQ27693607-2DB31AB6-59AB-4968-B4B9-F1A6DB347EE5Q27851628-CA7130B0-5B89-48CD-BD63-E4EDFAD2CC37Q27851710-EBD1C74C-B79B-4B6A-99F7-5890199CB763Q27852894-11AF724E-84E9-4F54-84B1-E930119EB8C9Q27853216-B0DFB91D-AC60-4FD4-8AFC-16290219B900Q28265862-22A85DE8-BB06-4423-85ED-2A1906EB7A39Q28305680-08616D64-876B-47D6-B82A-B65F271A21CDQ28601717-9548D254-C820-481A-96EB-CFC32E4972C2Q29395525-18C7EAA3-F0CB-42D7-A25F-7C785E909547Q30277902-BD9F1CE7-4BD7-4CD0-A04E-0097E9858AEEQ30358990-3A9640CF-6B68-4252-B826-DEB765CD9C2CQ33688428-275FEC37-8BAD-4BA1-AD0C-41D957F57D21Q33767369-716CD6F0-A8B5-4D3C-B4F7-1B6F318A4E28Q33861173-17E47B5A-7004-4772-A675-13DBEF8F5763Q33884726-96C95203-048B-4421-BDA5-045329F343B9Q34248355-BEE26152-BEB4-470F-A748-E427D804D019Q34307356-3A6CB5F6-27E6-49B1-B4B8-FB046A9D0594Q34344849-2AA38BDE-8C6E-4ECB-B41D-C7F0A314632EQ34374407-75C45F38-091B-46E9-ABDC-6D2C58217D53Q34459097-D870A8B7-4D65-40D1-8E22-C8CD52624FA8Q34659332-7E9349FC-D8B5-4D63-93A7-57D4C7261CB0Q34669370-E2ACCF66-B54C-4B7F-9B33-FC1746F87AAEQ34669746-FBB38838-0D73-4966-A30E-D78682C1A357Q34802932-202EBFB3-F724-4576-80FA-D7A3F0362422Q34938204-E96C3970-5B2B-4E90-B4A2-1D42BBB6E4C5Q35170413-972814A9-FCC9-49D5-8B18-0076AEE4AE5CQ35810176-C695A2F5-49F9-478E-B95C-FD57DD4CE49EQ35841043-4FCB22EC-71A7-4830-A3B9-B97232223846
P2860
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BRAF gene amplification can pr ...... oring the BRAF V600E mutation.
@ast
BRAF gene amplification can pr ...... oring the BRAF V600E mutation.
@en
BRAF gene amplification can pr ...... oring the BRAF V600E mutation.
@nl
type
label
BRAF gene amplification can pr ...... oring the BRAF V600E mutation.
@ast
BRAF gene amplification can pr ...... oring the BRAF V600E mutation.
@en
BRAF gene amplification can pr ...... oring the BRAF V600E mutation.
@nl
altLabel
BRAF Gene Amplification Can Pr ...... boring the BRAF V600E Mutation
@en
prefLabel
BRAF gene amplification can pr ...... oring the BRAF V600E mutation.
@ast
BRAF gene amplification can pr ...... oring the BRAF V600E mutation.
@en
BRAF gene amplification can pr ...... oring the BRAF V600E mutation.
@nl
P2093
P2860
P3181
P1433
P1476
BRAF gene amplification can pr ...... oring the BRAF V600E mutation.
@en
P2093
A John Iafrate
Dora Dias-Santagata
Jeffrey A Engelman
Jeffrey Settleman
Kristin Bergethon
Ryan B Corcoran
P2860
P3181
P356
10.1126/SCISIGNAL.2001148
P577
2010-11-23T00:00:00Z